# An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

> **NCT07456696** · PHASE3 · RECRUITING · sponsor: **Transcend Therapeutics** · enrollment: 300 (estimated)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** TSND-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07456696
- **Lead sponsor:** Transcend Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456696, "An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07456696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*